A study has revealed that a combination of Sabutoclax and a serotype chimeric adenovirus improved therapeutic efficacy in colorectal cancer cells through enhancing the delivery of mda-7/IL-24 (42). This evidence concerns the gene IL24 and colorectal cancer.